Last reviewed · How we verify
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid is a Small molecule drug developed by University of California, San Diego. It is currently FDA-approved.
At a glance
| Generic name | Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid |
|---|---|
| Sponsor | University of California, San Diego |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment (NA)
- A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer (PHASE2)
- Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis (PHASE4)
- REGULUS: MRI-guided Adaptive SABR for Liver Cancers (PHASE2)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions (NA)
- PET/MRI of Primary Sclerosing Cholangitis
- Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid CI brief — competitive landscape report
- Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid updates RSS · CI watch RSS
- University of California, San Diego portfolio CI
Frequently asked questions about Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
What is Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid?
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid is a Small molecule drug developed by University of California, San Diego.
Who makes Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid?
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid is developed and marketed by University of California, San Diego (see full University of California, San Diego pipeline at /company/university-of-california-san-diego).
What development phase is Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid in?
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid is FDA-approved (marketed).